Novo Nordisk shares rise on solid Q2 results

Diabetes drugmaker Novo Nordisk (NYSE:NVO) posted Street-beating second quarter results today, lifting its full-year sales forecast despite lingering concerns relating to U.S. drug pricing pressures.

Last year, the Danish company saw shares drop more than 40% after it slashed its long-term operating profit forecasts, citing price pressures in the U.S. market. Today, Novo Nordisk raised its full-year sales growth forecast in local currencies from o% – 3% to 1% – 3%.

Get the full story at our sister site, Drug Delivery Business News.

The post Novo Nordisk shares rise on solid Q2 results appeared first on MassDevice.

from MassDevice http://ift.tt/2vmhfRn